Skip to main content
. 2014 Dec 26;6(5):3195–3210. doi: 10.18632/oncotarget.3084

Table 1. Antiproliferative potencies of NRs, ATRA, 4-HPR, and FDA approved PCa drugs in androgen sensitive and castration resistant human prostate cancer cell lines.

Compound PWR-1E (μM) PC-3 (μM) C4-2B (μM) 22Rv1 (μM) LNCaP (μM) LNCaP (μM, DHT induced)
VN/14-1 69.18 36.3 9.76 12.88 11.32 12.88
VN/66-1 19.05 10.71 2.38 2.95 4.67 1.54
VNLG-145 25.11 4.26 2.14 2.23 2.45 2.23
VNLG-146 63.09 57.54 11.74 39.81 57.54 52.48
VNLG-147 71.53 2.95 2.66 2.04 1.86 1.41
VNLG-148 43.65 36.3 15.48 39.81 22.9 19.05
VNLG-152 47.86 5.62 1.54 3.23 2.45 1.86
VNLG-153 39.81 4.36 2.97 2.23 3.23 2.69
ATRA 75.3 36.3 11.74 25.11 47.86 39.81
4-HPR 1.07 3.54 3.11 3.23 2.69 2.45
Casodex 69.1 9.15 1.51 3.81 2.61 2.95
MDV3100 16.98 9.15 1.54 3.34 2.88 2.69
AA 20.15 7.62 1.47 2.97 2.45 2.69

Note: Cells were treated with listed compound (0.1 nmol/L-100 μmol/L) for 7 d and the GI50 values for the antiproliferative effects of the compounds were determined from dose response curves (by a nonlinear regression analysis using Graph Pad Prism). Data represents the results from six independent experiments for each cell line.